Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century — Live Feedhttps://www.live-feeds.com/feed/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-into-the-21st-centuryContinuously updated, source-cited coverage. Enveda Secures $311 Million Series E Funding at $2 Billion Valuationhttps://www.live-feeds.com/feed/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-into-the-21st-centuryhttps://www.live-feeds.com/feed/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-into-the-21st-century#u84427Sat, 26 Sep 2026 00:12:07 +0000Biotech startup Enveda has raised $311 million in Series E funding to advance AI-discovered, nature-derived medicines. The funding round values the company at $2 billion, doubling its previous valuation. Enveda intends to use the capital to move more candidates into clinical trials, focusing specifically on inflammatory diseases and late-stage obesity treatments. The company aims to develop medicines that address life after GLP-1 drugs and seeks to establish itself as a household name in the pharmaceutical industry.Why it mattersEnveda uses artificial intelligence to analyze the chemistry of t